Alan S. Wayne, MD
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alan S. Wayne, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02338050 · Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell TransplantationCenter for International Blood and Marrow Transplant Research · terminated · Acute Lymphoblastic Leukemia (ALL)
- Ph1NCT00085150 · LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or LymphomaNational Cancer Institute (NCI) · completed · Leukemia, Lymphoma · principal investigator
- Ph1NCT00077493 · BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaMedImmune LLC · suspended · Leukemia, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.